Retrospective price concession top-up payments announced

The Department of Health and Social Care (DHSC) has announced in Part VIIIE of the October 2026 Drug Tariff that 9 products dispensed between January and March 2026 will receive retrospective top-up payments because, according to Margins Survey data, the original concessionary prices granted for these products were found to be inappropriately low compared to their average pharmacy purchase prices for that month.

The retrospective top-up payments due on 1st October, will be applied automatically by the NHSBSA for the products listed in the table below. The adjustment will appear in pharmacies’ July 2026 Schedule of Payments displayed under ‘Details of other amounts authorised’ with the heading ‘Concessionary price top-up payment’.

Dispensing month Product name Original price concession granted Additional top-up amount
January 2026 Ivabradine 2.5mg tablets (56) £48.05 £6.42
January 2026 Propranolol 160mg modified-release capsules (28 pack) £5.90 £4.36
February 2026 Dipyridamole 200mg modified-release capsules (60) £39.78 £4.43
February 2026 Rosuvastatin 40mg tablets (28) £1.99 £2.55
March 2026 Captopril 50mg tablets (56) £38.01 £77.68
March 2026 Fesoterodine 8mg modified-release tablets (28) £2.83 £3.62
March 2026 Ivabradine 2.5mg tablets (56) £48.45 £3.23
March 2026 Labetalol 100mg tablets (56) £6.03 £9.63
March 2026 Leflunomide 10mg tablets (30) £9.34 £3.07
March 2026 Leflunomide 20mg tablets (30) £7.00 £5.88

Background

Following a review of the price concessions system  conducted by Community Pharmacy England and DHSC in 2022/23, a package of measures was introduced to improve the process including:

  • all products granted a concessionary price will be classified as ‘Discount Not Deducted’ for the month(s) in which they are on concession
  • any agreed prices for concessions requested on or after the 23rd of the month will be rolled over to the following month
  • a retrospective increased payment system for price concession lines where data subsequently identifies that the original price concessions granted were inappropriately low.

Further information can be found on our Price Concessions and Retrospective top-up payments webpages.